Bapineuzumab for mild to moderate Alzheimer’s disease: a meta-analysis of randomized controlled trials
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2377
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Bapineuzumab for mild to moderate Alzheimer’s disease: a meta-analysis of randomized controlled trials ; volume:17 ; number:1 ; day:4 ; month:4 ; year:2017 ; pages:1-13 ; date:12.2017
BMC neurology ; 17, Heft 1 (4.4.2017), 1-13, 12.2017
- Keyword
-
Hirnkrankheit
Neuropsychiatrie
Nervenkrankheit
- Creator
-
Abushouk, Abdelrahman Ibrahim
- Contributor
-
Elmaraezy, Ahmed
Aglan, Amro
Salama, Reham
Fouda, Samar
Fouda, Rana
AlSafadi, Ammar M.
SpringerLink (Online service)
- DOI
-
10.1186/s12883-017-0850-1
- URN
-
urn:nbn:de:1111-201704226756
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:32 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Abushouk, Abdelrahman Ibrahim
- Elmaraezy, Ahmed
- Aglan, Amro
- Salama, Reham
- Fouda, Samar
- Fouda, Rana
- AlSafadi, Ammar M.
- SpringerLink (Online service)
Other Objects (12)
Estimating attrition in mild-to-moderate Alzheimer’s disease and mild cognitive impairment clinical trials
Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials
Effect of TTP488 in patients with mild to moderate Alzheimer’s disease
Nutritional management for Alzheimer’s disease in all stages: mild, moderate, and severe
Dysphagia is closely related to frailty in mild-to-moderate Alzheimer’s disease
Acupuncture for patients with mild to moderate Alzheimer’s disease: a randomized controlled trial
The circadian rest-activity pattern predicts cognitive decline among mild-moderate Alzheimer’s disease patients
Balance impairment does not necessarily coexist with gait apraxia in mild and moderate Alzheimer’s disease
Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and mild-to-moderate Alzheimer’s disease
Drug candidates in clinical trials for Alzheimer’s disease
Imaging endpoints for clinical trials in Alzheimer’s disease
Heterogeneity of Alzheimer’s disease: consequence for drug trials?
Estimating attrition in mild-to-moderate Alzheimer’s disease and mild cognitive impairment clinical trials
Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials
Effect of TTP488 in patients with mild to moderate Alzheimer’s disease
Nutritional management for Alzheimer’s disease in all stages: mild, moderate, and severe
Dysphagia is closely related to frailty in mild-to-moderate Alzheimer’s disease
Acupuncture for patients with mild to moderate Alzheimer’s disease: a randomized controlled trial
The circadian rest-activity pattern predicts cognitive decline among mild-moderate Alzheimer’s disease patients
Balance impairment does not necessarily coexist with gait apraxia in mild and moderate Alzheimer’s disease
Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and mild-to-moderate Alzheimer’s disease
Drug candidates in clinical trials for Alzheimer’s disease
Imaging endpoints for clinical trials in Alzheimer’s disease
Heterogeneity of Alzheimer’s disease: consequence for drug trials?
Estimating attrition in mild-to-moderate Alzheimer’s disease and mild cognitive impairment clinical trials
Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials
Effect of TTP488 in patients with mild to moderate Alzheimer’s disease
Nutritional management for Alzheimer’s disease in all stages: mild, moderate, and severe
Dysphagia is closely related to frailty in mild-to-moderate Alzheimer’s disease
Acupuncture for patients with mild to moderate Alzheimer’s disease: a randomized controlled trial
The circadian rest-activity pattern predicts cognitive decline among mild-moderate Alzheimer’s disease patients
Balance impairment does not necessarily coexist with gait apraxia in mild and moderate Alzheimer’s disease
Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and mild-to-moderate Alzheimer’s disease
Drug candidates in clinical trials for Alzheimer’s disease
Imaging endpoints for clinical trials in Alzheimer’s disease